Taofeek K. Owonikoko | Hematology Oncology | Pittsburgh, PA

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Enrollment Status: Recruiting

Publish Date: February 26, 2025

Intervention Type: Other, Procedure, Biological, Drug

Study Phase: Not Applicable

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)

Enrollment Status: Recruiting

Publish Date: February 17, 2025

Intervention Type: Drug

Study Drug: Screening Platform

Study Phase: Phase 2/Phase 3

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Enrollment Status: Recruiting

Publish Date: July 03, 2024

Intervention Type: Other, Drug

Study Drug: Crizotinib

Study Phase: Phase 3

A Phase 1b Safety and Pharmacodynamic Study of MER Tyrosine Kinase Inhibitor, MRX-2843, in Combination With Osimertinib in Advanced EGFR Mutant Non-Small Cell Lung Cancer

Enrollment Status: Recruiting

Publish Date: May 01, 2024

Intervention Type: Drug

Study Drugs: Flt3/MerTK Inhibitor MRX-2843, Osimertinib

Study Phase: Phase 1

A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies

Enrollment Status: Recruiting

Publish Date: August 21, 2023

Molecular Analysis for Therapy Choice (MATCH)

Enrollment Status: Active_not_recruiting

Publish Date: February 25, 2025

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib

Study Phase: Phase 2

Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: February 25, 2025

Intervention Type: Other, Drug

Study Drug: Erlotinib Hydrochloride

Study Phase: Phase 3

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Enrollment Status: Active_not_recruiting

Publish Date: February 25, 2025

Intervention Type: Other, Procedure, Biological

Study Drug: Nivolumab

Study Phase: Phase 3

Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)

Enrollment Status: Active_not_recruiting

Publish Date: February 25, 2025

Intervention Type: Drug, Biological

Study Drugs: Carboplatin, Cisplatin, Etoposide, Nivolumab

Study Phase: Phase 2

A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)

Enrollment Status: Active_not_recruiting

Publish Date: February 04, 2025

Intervention Type: Drug

Study Drugs: Selpercatinib, Cabozantinib, Vandetanib

Study Phase: Phase 3

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab

Enrollment Status: Active_not_recruiting

Publish Date: January 30, 2025

Intervention Type: Other, Drug, Radiation, Procedure

Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide

Study Phase: Phase 3

A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)

Enrollment Status: Active_not_recruiting

Publish Date: January 20, 2025

Intervention Type: Drug

Study Drug: Selpercatinib

Study Phase: Phase 1/Phase 2

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Enrollment Status: Approved_for_marketing

Publish Date: January 17, 2025

Intervention Type: Drug

A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Enrollment Status: Active_not_recruiting

Publish Date: December 17, 2024

Intervention Type: Drug, Biological

Study Drugs: JDQ443, TNO155, Spartalizumab

Study Phase: Phase 1/Phase 2

A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants

Enrollment Status: Completed

Publish Date: December 10, 2024

Intervention Type: Drug

Study Drugs: Docetaxel, GSK3359609, Ipilimumab, Niraparib, Dostarlimab, Cobolimab

Study Phase: Phase 2

A Phase 1 Study of Pembrolizumab (MK-3475) in Combination With Recombinant Interleukin-12 in Patients With Solid Tumors

Enrollment Status: Active_not_recruiting

Publish Date: December 04, 2024

Intervention Type: Procedure, Biological

Study Phase: Phase 1

Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, Alone or in Combination With Other Agents, in Participants With Advanced Tumors

Enrollment Status: Terminated

Publish Date: November 26, 2024

Intervention Type: Drug

Study Drugs: GSK3901961, GSK3845097, Fludarabine, Cyclophosphamide

Study Phase: Phase 1

A Phase 1b Trial of Adaptive Stereotactic Body Radiotherapy in Combination with Durvalumab (MEDI4736), Platinum, and Etoposide in Extensive Stage Small Cell Lung Cancer

Enrollment Status: Suspended

Publish Date: October 10, 2024

Intervention Type: Drug, Device

Study Phase: Phase 1

A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)

Enrollment Status: Active_not_recruiting

Publish Date: October 08, 2024

Intervention Type: Drug

Study Drugs: Canakinumab, Pembrolizumab, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed

Study Phase: Phase 3

A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations

Enrollment Status: Terminated

Publish Date: June 13, 2024

Intervention Type: Drug

Study Drug: TPX-0046

Study Phase: Phase 1/Phase 2

A Phase I Study of M6620 (VX-970, Berzosertib) in Combination With Cisplatin and XRT in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)

Enrollment Status: Active_not_recruiting

Publish Date: May 17, 2024

Intervention Type: Procedure, Drug, Other, Radiation

Study Drugs: Berzosertib, Cisplatin

Study Phase: Phase 1

A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)

Enrollment Status: Active_not_recruiting

Publish Date: May 02, 2024

Intervention Type: Other, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 3

A Phase II, Multicenter Study of Oral MET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Enrollment Status: Completed

Publish Date: March 20, 2024

Intervention Type: Drug

Study Drug: INC280

Study Phase: Phase 2

A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination With Pembrolizumab in HLA-A2+ Participants With NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer

Enrollment Status: Terminated

Publish Date: February 23, 2024

Intervention Type: Drug

Study Drugs: Letetresgene autoleucel, Pembrolizumab

Study Phase: Phase 1/Phase 2

A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer

Enrollment Status: Terminated

Publish Date: October 17, 2023

Intervention Type: Drug

Study Phase: Phase 2

A Phase 1 Study of Palbociclib in Combination With Cisplatin or Carboplatin in Advanced Solid Malignancies

Enrollment Status: Completed

Publish Date: October 10, 2023

Intervention Type: Drug

Study Drugs: Carboplatin, Cisplatin, Palbociclib

Study Phase: Phase 1

A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Canakinumab in Combination With Docetaxel Versus Placebo in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Previously Treated With PD-(L)1 Inhibitors and Platinum-based Chemotherapy (CANOPY 2)

Enrollment Status: Terminated

Publish Date: August 21, 2023

Intervention Type: Drug, Other

Study Drugs: Canakinumab, Docetaxel

Study Phase: Phase 3

A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)

Enrollment Status: Completed

Publish Date: June 09, 2023

Intervention Type: Biological, Other

Study Drugs: Durvalumab, Tremelimumab

Study Phase: Phase 2

A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)

Enrollment Status: Completed

Publish Date: June 01, 2023

Intervention Type: Biological, Drug, Other

A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Terminated

Publish Date: September 21, 2022

Intervention Type: Drug, Dietary supplement, Biological

Study Drugs: Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Dexamethasone

Study Phase: Phase 2

Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors

Enrollment Status: Completed

Publish Date: July 20, 2022

Intervention Type: Drug

Study Phase: Phase 1

Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy

Enrollment Status: Terminated

Publish Date: June 09, 2022

Intervention Type: Drug

Study Drugs: Trilaciclib, Topotecan

Study Phase: Phase 1/Phase 2

A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)

Enrollment Status: Completed

Publish Date: November 04, 2021

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers

Enrollment Status: Completed

Publish Date: August 30, 2021

Intervention Type: Drug

Study Drugs: Ciforadenant, Ciforadenant+Atezolizumab

Study Phase: Phase 1

An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)

Enrollment Status: Completed

Publish Date: July 30, 2021

Intervention Type: Drug

Study Phase: Phase 2

A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)

Enrollment Status: Completed

Publish Date: June 23, 2021

Intervention Type: Other, Drug

Study Drug: Talazoparib

Study Phase: Phase 2

A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)

Enrollment Status: Completed

Publish Date: May 27, 2021

Intervention Type: Other, Drug

Study Drugs: Docetaxel, Palbociclib

Study Phase: Phase 2/Phase 3

A Phase I Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Completed

Publish Date: April 09, 2021

Intervention Type: Biological

Study Phase: Phase 1

A Phase I, Multicenter, Open-label, Single-sequence Drug-drug Interaction Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors

Enrollment Status: Completed

Publish Date: December 10, 2020

Intervention Type: Drug

Study Phase: Phase 1

A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Enrollment Status: Completed

Publish Date: December 09, 2020

Intervention Type: Biological, Drug

Study Phase: Phase 2/Phase 3

An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors

Enrollment Status: Terminated

Publish Date: October 19, 2020

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin

Enrollment Status: Completed

Publish Date: August 21, 2020

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase Ib/II, Open-label, Multicenter Trial With Oral cMET Inhibitor INC280 Alone and in Combination With Erlotinib Versus Platinum With Pemetrexed in Adult Patients With EGFR Mutated, cMET-amplified, Locally Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC) With Acquired Resistance to Prior EGFR Tyrosine Kinase Inhibitor (EGFR TKI)

Enrollment Status: Terminated

Publish Date: February 24, 2020

Intervention Type: Drug

Study Phase: Phase 1

An Intensive QT/QTc Study to Investigate the Effects of Rovalpituzumab Tesirine on Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer

Enrollment Status: Completed

Publish Date: September 24, 2018

Intervention Type: Drug

Study Phase: Phase 1

Dr. Taofeek K. Owonikoko

Overview

Insurance

Locations

Clinical Research

44 Clinical Trials

211 Total Publications

Oncology Hematology Association Inc

Oncology Hematology Association Inc

West Virginia University Medical Corporation

Areas of Expertise